



## Vaccine-Preventable Diseases Publications

(See polio, measles & rubella sections for additional publications)

1. Thompson K, Kalkowska D, Badizadegan K. Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative. *Gates Open Research* 2022; 6(5). doi:10.12688/gatesopenres.13524.1. <https://gatesopenresearch.org/articles/6-5/v1>. [version 1; awaiting peer review].
2. Thompson KM. Polio eradication: what kind of world do we want? *Lancet Infect Dis* 2022; 22(2): 161-3. doi:10.1016/S1473-3099(21)00458-8. [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(21\)00458-8/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00458-8/fulltext). Epub 20211011.
3. Thompson KM, Badizadegan K. Health economic analyses of secondary vaccine effects: a systematic review and policy insights. *Expert Rev Vaccines* 2022; 1-16. doi:10.1080/14760584.2022.2017287. <https://www.tandfonline.com/doi/full/10.1080/14760584.2022.2017287>. Epub 20220112.
4. Kalkowska DA, Thompson KM. Health and economic outcomes associated with polio vaccine policy options: 2019-2029. *Risk Anal* 2021; 41(2): 364-75. doi:10.1111/risa.13664. <https://www.ncbi.nlm.nih.gov/pubmed/33590519>. Epub 2021/02/15.
5. Secondary Vaccine Effects Workshop Planning Committee. NIAID workshop on secondary vaccine effects. *Nat Immunol* 2021; 22(11): 1363-6. doi:10.1038/s41590-021-01054-5. <https://www.ncbi.nlm.nih.gov/pubmed/34686866>. Epub: 20211022.
6. Thompson KM, Kalkowska DA. An updated economic analysis of the global polio eradication initiative. *Risk Analysis* 2021; 41(2): 393-406. doi:10.1111/risa.13665. <https://pubmed.ncbi.nlm.nih.gov/33590521>. Epub 2021/2/5.
7. Thompson KM, Kalkowska DA, Badizadegan K. Hypothetical emergence of poliovirus in 2020: Part 1. Consequences of policy decisions to respond using nonpharmaceutical interventions. *Expert Rev Vaccines* 2021. doi:10.1080/14760584.2021.1891888. <https://www.ncbi.nlm.nih.gov/pubmed/33624568>. Epub 2021/02/25.
8. Thompson KM, Kalkowska DA, Badizadegan K. Hypothetical emergence of poliovirus in 2020: Part 2. Exploration of the potential role of vaccines in control and eradication. *Expert Rev Vaccines* 2021. doi:10.1080/14760584.2021.1891889. <https://www.ncbi.nlm.nih.gov/pubmed/33599178>. Epub 2021/02/19.
9. Ochalek J, Claxton K, Lomas J, Thompson KM. Valuing health outcomes: developing better defaults based on health opportunity costs. *Expert Rev Pharmacoecon Outcomes Res* 2020: 1-8. doi:10.1080/14737167.2020.1812387. <https://www.ncbi.nlm.nih.gov/pubmed/32954900>. Epub 2020/09/22.
10. Thompson KM, Orenstein WA, Hinman AR. An opportunity to incentivize innovation to increase vaccine safety in the United States by improving vaccine delivery using vaccine patches. *Vaccine* 2020. doi:10.1016/j.vaccine.2020.04.044. <https://www.sciencedirect.com/science/article/pii/S0264410X20305387?via%3Dihub>. Epub 2020 Apr 21.
11. Badizadegan K, Goodson JL, Rota PA, Thompson KM. The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization. *Expert Rev Vaccines* 2020; 19(2): 175-94. doi:10.1080/14760584.2020.1732215. <https://www.ncbi.nlm.nih.gov/pubmed/32182145>. Epub 2020 Mar 17.
12. Thompson KM, Orenstein WA, Hinman AR. Performance of the United States Vaccine Injury Compensation Program (VICP): 1988-2019. *Vaccine* 2020. doi: 10.1016/j.vaccine.2020.01.042. <https://doi.org/10.1016/j.vaccine.2020.01.042>. Epub 2020 Jan 22.



13. Thompson KM, Gellin BG, Hinman AR, Orenstein WA. The National Vaccine Advisory Committee at 30: impact and opportunity. *Vaccine* 2018; **36**(11): 1330-44. doi:10.1016/j.vaccine.2018.01.068. <https://www.ncbi.nlm.nih.gov/pubmed/29422369>
14. Ozawa S, Yemeke TT, Thompson KM. Systematic review of the incremental costs of interventions that increase immunization coverage. *Vaccine* 2018; **36**(25): 3641-9. doi:10.1016/j.vaccine.2018.05.030. <https://www.ncbi.nlm.nih.gov/pubmed/29754699>
15. National Vaccine Advisory Committee. Strengthening the effectiveness of national, state, and local efforts to improve HPV vaccination coverage in the United States: recommendations From the National Vaccine Advisory Committee. *Public Health Rep* 2018; **133**(5): 543-50. doi:10.1177/0033354918793629. <https://www.ncbi.nlm.nih.gov/pubmed/30091942>
16. Duintjer Tebbens RJ, Thompson KM. Using integrated modeling to support the global eradication of vaccine-preventable diseases. *System Dynamics Review* 2018; **34**(1-2): 78-120. doi:10.1002/sdr.1589. <https://onlinelibrary.wiley.com/doi/abs/10.1002/sdr.1589>
17. Beigi RH, Omer SB, Thompson KM. Key steps forward for maternal immunization: policy making in action. *Vaccine* 2018; **36**(12): 1521-3. doi:10.1016/j.vaccine.2018.02.041. <https://www.ncbi.nlm.nih.gov/pubmed/29456018>
18. National Vaccine Advisory Committee. Evaluation of the 2010 National Vaccine Plan mid-course review: recommendations From the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on February 7, 2017. *Public Health Rep* 2017; **132**(4): 411-30. doi:10.1177/0033354917714233. <https://www.ncbi.nlm.nih.gov/pubmed/28644068>
19. National Vaccine Advisory Committee. Overcoming barriers and identifying opportunities for developing maternal immunizations: recommendations from the National Vaccine Advisory Committee. *Public Health Rep* 2017; **132**(3): 271-84. doi:10.1177/0033354917698118. <https://www.ncbi.nlm.nih.gov/pubmed/28379782>
20. Thompson KM, Logan GE, Florida SRT. Characterization of heterogeneity in childhood immunization coverage in central Florida using immunization registry data. *Risk Anal* 2016; **36**(7): 1418-26. doi:10.1111/risa.12424. <https://www.ncbi.nlm.nih.gov/pubmed/26033542>
21. Thompson KM, Duintjer Tebbens RJ. Framework for optimal global vaccine stockpile design for vaccine-preventable diseases: application to measles and cholera vaccines as contrasting examples. *Risk Anal* 2016; **36**(7): 1487-509. doi:10.1111/risa.12265. <https://www.ncbi.nlm.nih.gov/pubmed/25109229>
22. National Vaccine Advisory Committee. A call for greater consideration for the role of vaccines in national strategies to combat antibiotic-resistant bacteria: recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 10, 2015. *Public Health Rep* 2016; **131**(1): 11-6. doi:10.1177/003335491613100105. <https://www.ncbi.nlm.nih.gov/pubmed/26843664>
23. National Vaccine Advisory Committee. Overcoming barriers to low HPV vaccine uptake in the United States: recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 9, 2015. *Public Health Rep* 2016; **131**(1): 17-25. doi:10.1177/003335491613100106. <https://www.ncbi.nlm.nih.gov/pubmed/26843665>
24. National Vaccine Advisory Committee. Assessing the state of vaccine confidence in the United States: recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 9, 2015. *Public Health Rep* 2015; **130**(6): 573-95. doi:10.1177/003335491513000606. <https://www.ncbi.nlm.nih.gov/pubmed/26556929>
25. Thompson KM, Duintjer Tebbens RJ, Chaignat CL, Hill A, Costa AJ, Badizadegan K, Namgyal P, Hutubessy RC. Managing cholera as a preventable global threat. *J Vaccines Vaccin* 2013; **4**(183): 1000183. doi:10.4172/2157-7560.1000183. <https://www.longdom.org/open-access/managing-cholera-as-a-preventable-global-threat-2157-7560.1000183.pdf>
26. Thompson KM, Duintjer Tebbens RJ. Development of investment cases for globally-coordinated management of infectious diseases. *J Vaccines Vaccin* 2012; **3**(8): 164. doi:10.4172/2157-7560.1000164. <https://www.longdom.org/open-access/development-of-investment-cases-for-globally-coordinated-management-of-infectious-diseases-2157-7560.1000164.pdf>
27. Thompson KM. Valuing prevention as the new paradigm in global health: Managing population immunity for vaccine-preventable diseases. *ICU Management* 2012; **12**(4): 9-11.



28. Thompson KM, Rabinovich R, Conteh L, Emerson CI, Hall BF, Singer PA, Vijayaraghavan M, Walker D. Group report: developing an eradication investment case. In: Cochi SL, Dowdle WR, eds. *Disease Eradication in the 21st Century: Implications for Global Health*. Cambridge, MA: MIT Press; 2011: 133-48.
29. Thompson KM, Duintjer Tebbens RJ. Economic evaluation of the benefits and costs of disease elimination and eradication initiatives. In: Cochi SL, Dowdle WR, eds. *Disease Eradication in the 21st Century: Implications for Global Health*. Cambridge, MA: MIT Press; 2011: 115-30.
30. Duintjer Tebbens RJ, Thompson KM. Priority shifting and the dynamics of managing eradicable infectious diseases. *Manag Sci* 2009; **55**(4): 650-63. doi:10.1287/mnsc.1080.0965. <https://pubsonline.informs.org/doi/10.1287/mnsc.1080.0965>
31. Duintjer Tebbens RJ, Thompson KM, Hunink MG, Mazzuchi TA, Lewandowski D, Kurowicka D, Cooke RM. Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs. *Med Decis Making* 2008; **28**(2): 182-200. doi:10.1177/0272989X07311752. <https://www.ncbi.nlm.nih.gov/pubmed/18349438>
32. Nigrovic LE, Thompson KM. The Lyme vaccine: a cautionary tale. *Epidemiol Infect* 2007; **135**(1): 1-8. doi:10.1017/s0950268806007096. <https://www.ncbi.nlm.nih.gov/pubmed/16893489>
33. Lieu TA, Thompson KM, Prosser LA, O'Brien MA, Yusuf HR, Shefer AM, Weinstein MC, Rickert DL. Emerging issues in vaccine economics: perspectives from the USA. *Expert Rev Vaccines* 2002; **1**(4): 433-42. doi:10.1586/14760584.1.4.433. <https://www.ncbi.nlm.nih.gov/pubmed/12901581>